130 results about "Proteomic Profiling" patented technology

The invention relates to a quantitative method for occupancy of N-bond sialylated sugar chains on glycoprotein and an application of the quantitative method in hepatoma marker screening. The method comprises the following steps: two biological samples containing glycoprotein under a same state are taken, then a sodium periodate solution is used for respectively processing the two biological samples for performing differential oxidation, then a hydrazide chemical method on protein is used for enriching glycoprotein in the samples after differential oxidation, then differences of different stable isotopes can be used for labeling the glycopeptide on hydrazide microspheres, and peptide-N-glycosidase (PNGase) is used for processing, and finally mass spectrometry is carried out on mixing difference-labeled N-glycopeptide so as to quantify the occupancy of N-bond sialylated sugar chains. The method can be used for glycosylation-modified proteomics analysis, can simultaneously obtain the corresponding glycoprotein, glycopeptide and glycosylation bit identification results, and especially can be used for screening of a latent biological marker for hepatic cellular cancer(HCC). The method has the advantages of simpleness and high efficiency.

The invention provides a polypeptide chip, which comprises a substrate and n polypeptides distributed on the substrate in an array, each polypeptide sequence has 10-20 amino acids, a group consistingof sequences of first to nth polypeptides covers at least 95% of a viral protein sequence, the adjacent polypeptides have an overlap of 3-8 amino acids, and n is 810-1370. According to the method, proteomics and system biology strategies are adopted, all coded protein sequences of COVID-19 are extracted from NCBI data, an SARS-CoV-2 virus proteome polypeptide chip is designed and prepared, and panoramic scanning of all SARS-CoV-2 virus antibodies in blood of a novel pneumonia virus infected patient is achieved.

A passive, hydrodynamic technique implemented using a microfluidic device to perform co-encapsulation of samples in droplets and sorting of said droplets is described herein. The hydrodynamic technique utilizes laminar flows and high shear liquid-liquid interfaces at a microfluidic junction to encapsulate samples in the droplets. A sorting mechanism is implemented to separate sample droplets from empty droplets. This technique can achieve a one-one-one encapsulation efficiency of about 80% and can significantly improve the droplet sequencing and related applications in single cell genomics and proteomics.

The invention relates to the field of immunology, and discloses a tumor individualized specific therapeutic vaccine and a preparation method thereof. Through MCTL proteomics dendritic cell cluster target detection, a tumor specific molecular target in a subject is analyzed, a therapeutic target is synthesized in vitro and co-cultured with autoimmune cells of the cultured subject, and the therapeutic vaccine is prepared. After the therapeutic vaccine is transfused back to a subject, tumor cells are specifically killed, immune balance is rebuilt, the purpose of effectively treating tumors is achieved, and the therapeutic vaccine has wide clinical application prospects.

The invention belongs to the technical field of scientific workflows supported by computers and particularly discloses a workflow matching and finding system, based on provenance, facing proteomic data analysis. When a proteomic data analysis process is set up, the system sufficiently utilizes collected historical process information and provenance information relevant to the historical process information, realizes reuse of knowledge, reduces time consumption and energy consumption at process setting-up time, and quickens the progress of data analysis experiments. The processing process inside the system can be divided into three steps: using scientific workflows based on tasks to describe experiment tasks; utilizing a process matching and provenance information discovery algorithm mechanism to extract the instantiated process and the provenance information of the instantiated process; integrating the extracted process information and showing the information to researchers, and requiring the researchers to reuse or modify the historical process configuration information.

The invention discloses a kit for detecting an anti-moesin antibody. The kit comprises a solid-phase carrier and a moesin antigenic protein, wherein the moesin antigenic protein is a full-length human moesin. The kit can be applied to a method for early prediction and severity evaluation of connective tissue disease (CTD)-related lung involvement and evaluation is performed by mainly sampling a biological sample of a subject and detecting the quantity of the anti-moesin antibodies in the biological sample. The moesin is prepared by proteomics technology and gene recombination technology and an enzyme-linked immunosorbent assay (ELISA) detection kit for detecting the anti-moesin antibody is provided. The detectable rate of the kit for the CTD-related lung involvement is up to 51.7 percent.

The invention aims to provide a proteomics analysis method based on SP3 enzymolysis. The method comprises the following steps: adding lysate into cells of a sample to be detected for denaturation; wherein the component of the lysis solution is 50mM of 4-hydroxyethylpiperazine ethanesulfonic acid; 1% lauryl sodium sulfate, 1% of polyethylene glycol octyl phenyl ether; 1% Tween 20, 1% of ethyl phenyl polyethylene glycol; 5 mM of ethylenediamine tetraacetic acid; 50mM sodium chloride, 1% of glycerol; a 1 * protease inhibitor; and 5 mM dithiothreitol, adding a magnetic bead replacement lysate intothe denatured sample; removing a denaturant influencing trypsin activity; after the replacement is finished, carrying out lysine protease enzymolysis and trypsin enzymolysis on the denatured sample;the method has the advantages that automation can be achieved, the repeatability of experiments of different batches is improved, and meanwhile the flux is improved, and meanwhile the method is not inferior to a traditional protein enzymolysis method in terms of evaluation indexes such as the peptide fragment recovery rate and the sample repeatability.

The invention discloses a sample pretreatment method for plant metabolome analysis. The method comprises the following steps: sampling and inactivating, sample homogenizing and grinding, centrifugal filtration and the like; various tissue parts are separately sampled, are frozen and inactivated quickly by adopting liquid nitrogen, and are homogenized and ground by high-speed oscillation in a liquid nitrogen environment; a mixed sample is extracted by adopting ultrasonic in an assistant manner after being obtained; finally, protein is removed through high-speed centrifugation. According to the sample pretreatment method, the defects of temperature change, easiness in pollution, serious sample waste, relatively poor repeatability, uneven sample mixing, relatively low work efficiency, high operating danger coefficient, high requirements on the proficiency and work experience of operating personnel and the like are overcome. The sample pretreatment method can be well applied to hard tissue sampling, homogenizing, grinding and extracting of woody plant samples of tea trees and the like, and is a rapid, nondestructive and pollution-free sample pretreatment technology for performing a metabonomics analysis test. The sample pretreatment method can also be applied to a quality component analysis, RNA (Ribonucleic Acid) extraction, a proteomics analysis and the like.

The invention relates to a photoinduced cell covalent labeled fluorescent molecule, and a preparation method and application thereof, in particular to a compound as shown in the following formula (I), or a tautomer, an enantiomer, an enantiomer, a diastereomer, a racemate, a precursor compound, an isotope compound and various forms of salts or hydrates thereof. The compounds can be used for preparing light-induced covalent labeled fluorescent probes and are used for positioning and imaging subcellular organelles in cell biology. The light-induced covalent labeled fluorescent probe has important application potential and outstanding practical value in cell biology research, proteomics research and dynamic change research of biomacromolecules.

The invention discloses a marker for rapidly predicting whether a COVID-19 patient suffers from light-to-severe progression or not, a kit thereof and an establishment method of the marker. According to the method, the severity of the condition of an early-stage COVID-19 patient is predicted through proteomics data, then potential critical patients are screened, and specific analysis can be carried out only by obtaining the three feature data of OAF, MB and DDT of the patient when the patient is admitted to hospital. The marker and the detection kit can timely, rapidly, objectively and accurately predict the severity of the condition of a COVID-19 patient and whether the disease progresses from light to severe, and assist medical staff in timely finding potential critical patients to allocate enough medical resources and attention, which are advantages that a traditional evaluation mode does not have. Therefore, the invention has great clinical application value for early rapid prediction and screening of the potential critical patients of COVID-19.

The invention relates to a method for screening a severe preeclampsia patient in an early pregnancy, which adopts plasma fibronectin FN and complement 4b of a pregnant woman in the early pregnancy as early pregnancy plasma markers for predicting sPE, and establishes a prediction model for predicting or assisting in predicting whether the pregnant woman progresses to the sPE patient, so that the sPE can be accurately predicted. The method has the beneficial effects that the plasma biological marker of the sPE pregnant woman at the early pregnancy stage is searched by adopting an MS-based proteomics method, and the differential expression plasma marker obtained by proteomics analysis is verified through a commercially available ELISA kit;through proteomics analysis and ELISA verification, based on the difference indexes in the pregnant woman baseline features and the difference indexes in the pregnant woman plasma biomarkers in the prospective queue, an early pregnancy prediction model of sPE is constructed, the prediction accuracy of sPE is improved, clinical early intervention is guided, the incidence rate of PE is reduced as much as possible, and adverse pregnancy events are reduced.

The present invention relates to the treatment of Dengue virus infection. To gain insight into the molecular and cellular function of the DENV RC, the inventors generated a tagged NS1 DENV replicon in order to identify associated host proteins during active viral replication. This allowed an unprecedented mapping of the NS1-host interactome in a relevant system and the identification of cellular modules targeted by the DENV RC. By combining 10 these proteomics data with gene silencing experiments, they identified a set of Host Dependency Factors (HDFs) and Host Restriction Factors (HRFs) that critically impact DENV infection. More they tested the NGI-1 molecule for its OST complex inhibition properties and showed that this molecule can be used to treat Dengue virus infection. Thus, the invention relates to an inhibitor of the OST complex and/or of the CCT complex and/or of 15 RACK1 for use in the treatment of dengue virus infection in a subject in need thereof.

Described herein is a microphysiological system for models of disease. Specifically, induced pluripotent stem cells (iPSCs) and iPSC-derived cells, including those obtained from disease patients, are seeded onto microfluidic “chip” devices to study cellular development and disease pathogenesis. Herein, neurodegenerative disease modeling, including Parkinson's Disease (PD) is shown to reproduce key PD pathology in a vascularized human model that contains neurons relating to PD pathology. Such compositions and methods are used for research for PD biomarkers, patient screening for PD risk assessment, and therapeutic discovery and testing. A panel of biomarkers are generated through analysis of living PD-chips by neural activity, whole transcriptomic, proteomic, and metabolomic analysis, and functional enzyme tests of media and tissue. Introducing therapeutics through a vasculature channel, coupled with blood brain barrier penetration studies can be assessed for efficacy in the human neural cells present in the PD-Chip.

Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.

The present invention discloses a diagnostic marker for aortic dissection. The diagnostic marker comprises at least one of a protein inhibitor 16 and fibrinogen-like protein 1. The present invention also discloses an application of the diagnostic marker for aortic dissection in diagnosis of the aortic dissection, an application of the diagnostic marker for aortic dissection in production of diagnostic products for diagnosis of the aortic dissection, an application of the diagnostic marker for aortic dissection for distinguishing the aortic dissection from acute coronary syndrome and an application of the diagnostic marker for aortic dissection in production of diagnostic products for distinguishing the aortic dissection from acute coronary syndrome. The diagnostic marker for aortic dissection is screened out by proteomic principles, and verified by a large number of samples. The diagnostic marker for aortic dissection can effectively improve diagnostic rate of the aortic dissection anddiagnostic rate for distinguishing the aortic dissection from acute coronary syndrome.

The invention provides a hypoxia-related gene marker combination for hepatocellular carcinoma and application thereof. A hypoxia score obtained by using the hypoxia-related gene marker combination can better reflect the hypoxia exposure condition of hepatocellular carcinoma tissues, and the hepatocellular carcinoma is subjected to typing and prognosis analysis. Meanwhile, the hypoxia-related gene marker combination is used for comprehensively exploring the change of hypoxia-related molecular markers in the hepatocellular carcinoma from multiple aspects of genomics, epigenomics, transcriptomics, proteomics and the like, a more complete hepatocellular carcinoma hypoxia-related molecular landscape is described, meanwhile, the immune microenvironment change of liver cancer is analyzed, and more valuable information is provided for diagnosis and treatment of the hepatocellular carcinoma.